T2 BIOSYSTEMS, INC. (NASDAQ:TTOO) Files An 8-K Other Events
Item 8.01 Other Events
On November 20, 2019 T2 Biosystems, Inc. (the Company) issued a press release announcing the granting of a CE-Mark to the T2Resistance Panel which will allow the Company to market the T2Resistance Panel within the European Economic Area. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| 99.1 | | Press Release issued November 20, 2019 |
T2 Biosystems, Inc. Exhibit
EX-99.1 2 d838072dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 MEDIA RELEASE T2 Biosystems Announces Granting of CE-Mark for T2Resistance Panel The T2Resistance Panel is the only direct-from-blood diagnostic designed to detect genetic markers associated with antibiotic-resistant bloodstream infections LEXINGTON,…
To view the full exhibit click here
About T2 BIOSYSTEMS, INC. (NASDAQ:TTOO)
T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company’s initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.
